Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.

Source:http://linkedlifedata.com/resource/pubmed/id/15625365

J. Clin. Oncol. 2005 Jan 1 23 1 105-12

Download in:

View as

Triples

General Info

PMID
15625365